Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy With or Without Preventive Anticoagulation in Metastatic Pancreatic Cancer
2007-002115-59Phase 3Completed
- Sponsor
- GERCOR
- Start
- Sep 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of dalteparin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by GERCOR. Primary endpoints: Number of thromboembolic events and Event-free survival from thromboembolism. Started Sep 2007; status: completed.
02
Drugs
dalteparin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2007-002115-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002115-59.